Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines:: Identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors

被引:90
|
作者
Boschelli, DH
Wu, ZP
Klutchko, SR
Showalter, HDH
Hamby, JM
Lu, GH
Major, TC
Dahring, TK
Batley, B
Panek, RL
Keiser, J
Hartl, BG
Kraker, AJ
Klohs, WD
Roberts, BJ
Patmore, S
Elliott, WL
Steinkampf, R
Bradford, LA
Hallak, H
Doherty, AM
机构
[1] Parke Davis Pharmaceut Res, Dept Med Chem, Ann Arbor, MI 48105 USA
[2] Parke Davis Pharmaceut Res, Dept Canc Res, Ann Arbor, MI 48105 USA
[3] Parke Davis Pharmaceut Res, Dept Vasc & Cardiac Dis, Ann Arbor, MI 48105 USA
[4] Parke Davis Pharmaceut Res, Dept Pharmacokinet & Drug Metab, Ann Arbor, MI 48105 USA
关键词
D O I
10.1021/jm980398y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Screening of a compound library led to the identification of 2-amino-6-(2,6-dichlorophenyl)-8-methylpyrido[2,3-d]pyrimidine (1) as a inhibitor of the platelet-derived growth factor receptor (PDGFr), fibroblast growth factor receptor (FGFr), and c-src tyrosine kinases (TKs). Replacement of the primary amino group at C-2 of 1 with a 4-(N,N-diethylaminoethoxy)phenylamino group yielded 2a, which had greatly increased activity against all three TKs. In the present work, variation of the aromatic group at C-6 and of the alkyl group at N-8 of the pyrido[2,3-d]pyrimidine core provided several analogues that retained potency, including derivatives that were biased toward inhibition of the TK activity of PDGFr. Analogues of 2a with a 3-thiophene or an unsubstituted phenyl group at C-6 were the most potent inhibitors. Compound 54, which had IC50 values of 31, 88, and 31 nM against PDGFr, FGFr, and c-src TK activity, respectively, was active in a variety of PDGF-dependent cellular assays and blocked the in vivo growth of three PDGF-dependent tumor lines.
引用
收藏
页码:4365 / 4377
页数:13
相关论文
共 50 条
  • [1] Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines
    Wu, Z
    Boschelli, D
    Klutchko, S
    Lu, G
    Panek, R
    Kraker, A
    Doherty, A
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 201 - MEDI
  • [2] Inhibitors of the platelet-derived growth factor receptor tyrosine kinase
    Bilder, GE
    Rojas, CJ
    CARDIOVASCULAR DRUG REVIEWS, 1996, 14 (04): : 380 - 399
  • [3] A potent inhibitor of platelet-derived growth factor receptor tyrosine kinase
    Min, DS
    Lee, YH
    Kang, LW
    Byoun, CH
    Chang, JS
    Ryn, SH
    Suh, PG
    MOLECULES AND CELLS, 1996, 6 (04) : 463 - 468
  • [4] In vitro characterization of a novel series of platelet-derived growth factor receptor tyrosine kinase inhibitors
    Sawutz, DG
    Bode, DC
    Briggs, GM
    Reid, JR
    Canniff, P
    Caldwell, L
    Faltynek, CR
    Miller, D
    Dunn, JA
    deGaravilla, L
    Guiles, JW
    Weigelt, C
    Michne, W
    Treasurywala, AM
    Silver, PJ
    BIOCHEMICAL PHARMACOLOGY, 1996, 51 (12) : 1631 - 1638
  • [5] CoMFA analysis of pyrrolo[2,3-d]pyrimidines and furo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors
    Gangjee, Aleem
    Raghavan, Sudhir
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [6] Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
    Hamby, JM
    Connolly, CJC
    Schroeder, MC
    Winters, RT
    Showalter, HDH
    Panek, RL
    Major, TC
    Olsewski, B
    Ryan, MJ
    Dahring, T
    Lu, GH
    Keiser, J
    Amar, A
    Shen, C
    Kraker, AJ
    Slintak, V
    Nelson, JM
    Fry, DW
    Bradford, L
    Hallak, H
    Doherty, AM
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (15) : 2296 - 2303
  • [7] Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: Synthesis and SAR study as tyrosine kinase c-Met inhibitors
    Wu, Kui
    Ai, Jing
    Liu, Qiufeng
    Chen, TianTian
    Zhao, Ailing
    Peng, Xia
    Wang, Yuanxiang
    Ji, Yinchun
    Yao, Qizheng
    Xu, Yechun
    Geng, Meiyu
    Zhang, Ao
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (20) : 6368 - 6372
  • [8] Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
    Connolly, CJC
    Hamby, JM
    Schroeder, MC
    Barvian, M
    Lu, GH
    Panek, RL
    Amar, A
    Shen, C
    Kraker, AJ
    Fry, DW
    Klohs, WD
    Doherty, AM
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (18) : 2415 - 2420
  • [9] Structure-activity relationships of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.
    Connolly, CJC
    Hamby, JM
    Schroeder, MC
    Lu, GH
    Panek, L
    Amar, A
    Shen, C
    Kraker, AJ
    Doherty, AM
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 211 : 193 - MEDI
  • [10] TYROSINE KINASE INHIBITORS .7. 7-AMINO-4-(PHENYLAMINO)PYRIDO[4,3-D]PYRIMIDINES AND 7-AMINO-4-[(PHENYLMETHYL)AMINO]PYRIDO[4,3-D]PYRIMIDINES - A NEW CLASS OF INHIBITORS OF THE TYROSINE KINASE-ACTIVITY OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR
    THOMPSON, AM
    BRIDGES, AJ
    FRY, DW
    KRAKER, AJ
    DENNY, WA
    JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (19) : 3780 - 3788